Unfractionated heparin during elective PCI: fixed dose or weight adjusted?

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Optimal unfractionated heparin (UFH) dosing for elective percutaneous coronary intervention (PCI) in stable angina patients remains unclear.
• Current guidelines lack robust data, necessitating further investigation into heparin strategies.
• Transradial PCI is increasingly common, requiring specific procedural anticoagulation assessment.

Purpose of the Study:

• To compare the efficacy and safety of a fixed UFH dose versus a weight-adjusted UFH dose during elective transradial PCI.
• To evaluate troponin I release as the primary endpoint for assessing myocardial injury.
• To determine if a reduced heparin dose is non-inferior to standard dosing in this patient population.

Main Methods:

• Retrospective analysis of a PCI database including 698 patients with stable angina undergoing elective transradial PCI.
• Patients were divided into two groups: fixed UFH dose (3000 U) and weight-adjusted UFH dose (70 U/kg).
• Primary endpoint was troponin I release; secondary endpoints included ischemic events and bleeding complications.

Main Results:

• No significant difference in median troponin I levels between the fixed-dose (0.17 ng/mL) and weight-adjusted dose (0.14 ng/mL) groups (P=0.21).
• Similar proportions of troponin-positive patients were observed in both groups (61.9% vs. 58.1%; P=0.37).
• No deaths, major ischemic events, or bleeding complications requiring transfusion or delaying discharge occurred.

Conclusions:

• A reduced, fixed dose of periprocedural UFH is associated with similar post-PCI troponin levels compared to standard weight-adjusted dosing.
• These findings challenge the necessity of standard weight-adjusted heparin dosing in elective transradial PCI.
• Further clinical trials are warranted to definitively establish optimal UFH dosage for PCI.